schema:articleBody
| - Brazil's health regulatory agency said Tuesday it had approved the Pfizer-BioNTech Covid-19 vaccine for widespread use, as the country races to secure enough doses to contain one of the world's worst outbreaks. "It gives me great pleasure to announce that after a 17-day review, (regulators) have granted the first approval in the Americas for widespread use of a vaccine against Covid-19," said Antonio Barra Torres, the director of federal health regulator Anvisa, underlining that the approval was definitive and not only for emergency use. However, the vaccine is not yet available in Brazil, which is so far using two others: Chinese-developed CoronaVac and one developed by Oxford University and British-Swedish pharmaceutical firm AstraZeneca. The approval came a day after media reports said Pfizer representatives had told Brazilian senators that the country's regulatory requirements were excessively strict. Pfizer reportedly objected to the government's insistence on the right to hold the company liable for any side effects the vaccine may cause. Anvisa's statement did not mention the issue, which has been a sticking point in Brazil's negotiations with Pfizer. President Jair Bolsonaro, whose critics accuse him of fueling anti-vaccine skepticism, joked at one point of the Pfizer vaccine, "If it turns you into an alligator, that's your problem." The far-right leader has faced criticism for vaccine shortages that have forced several cities to halt their immunization drives after a little over a month. Brazil has vaccinated about 5.9 million people so far, or 2.8 percent of its population of 212 million. More than 247,000 people have died of Covid-19 in Brazil, the second-highest death toll, after the United States. bur-jhb/dw
|